Dec 28, 2012, 08.26 AM IST
Drug firm Aurobindo Pharma said it has received final approval by the US health regulator to manufacture and market Nafcillin for injection used for treating bacterial infections in the American market.
"The products are ready for launch," it added. These abbreviated new drug applications (ANDAs) have been approved out of the company's unit XII formulation facility in Hyderabad and will be marketed and sold by its US subsidiary AuroMedics Pharma LLC, Aurobindo Pharma said. The company currently has a total of 171 ANDA approvals (145 final approvals including 2 from Aurolife Pharma LLC and 26 tentative approvals), it added.
"Nafcillin for injection is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug," the company said. Shares of Aurobindo Pharma were trading at Rs 192.40 per scrip on BSE, down 0.31 per cent from its previous close.
Aurobindo Pharm stock price
On December 09, 2013, Aurobindo Pharma closed at Rs 306.00, down Rs 0.55, or 0.18 percent. The 52-week high of the share was Rs 312.00 and the 52-week low was Rs 127.15.
The company's trailing 12-month (TTM) EPS was at Rs 21.67 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 14.12. The latest book value of the company is Rs 100.93 per share. At current value, the price-to-book value of the company is 3.03.
Tags: Aurobindo Pharma, US health regulator, US Food & Drug Administration, USFDA, Nafcillin, injection
Action in Aurobindo Pharma
Video of the day
Dec 6 2013, 15:02
- in MARKET OUTLOOK
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.